Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GOOGL$281.29-1.31(-0.46%)UPDATE 2-Alphabet takes $548 million stake in partner Qualcomm in data center push7:42:43 AM ETPEP$139.16-3.61(-2.53%)If You Invested $300,000 in Coca-Cola, PepsiCo and Keurig Dr Pepper, Here's What They'd Pay7:37:28 AM ETNVDA$188.74+7.15(+3.94%)Nvidia Just Had Its Worst Day Since DeepSeek, Losing About $450 Billion7:37:04 AM ETCMCSA$24.25-0.73(-2.92%)UPDATE 1-UK broadcaster Sky received security threat, as alerts sweep Europe7:35:58 AM ETMRNA$252.92+11.72(+4.86%)Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit7:34:00 AM ETPLTR$158.73+3.82(+2.47%)Prediction: $5,000 Invested in Palantir Will Be Worth This Much by 20317:33:00 AM ETBN$41.74-0.02(-0.05%)Brookfield Asset Management Fundraises $25 Billion in Quarter, Led by Infrastructure Strategies7:30:00 AM ETCMCSA$24.25-0.73(-2.92%)UK broadcaster Sky says it received security threat7:28:07 AM ETMMM$186.35-1.42(-0.76%)3M: Strong Order Momentum And Improving Execution Point To More Upside7:25:39 AM ETEQIX$1,001.00+3.65(+0.37%)Wall Street's Loudest Voices Split on Whether the AI Trade Is Finished7:22:47 AM ETTGT$155.35-2.58(-1.63%)Own Target Stock by Nov. 9 to Qualify for Its Dec. 1 Dividend. Here's How Many Shares of the Dividend King You'd Need for $2,000 in Yearly Dividends.7:22:00 AM ETKO$94.09-1.78(-1.86%)Coca-Cola Has Raised Its Dividend for 64 Straight Years. Here's What $10,000 Will Pay You in 2027.7:22:00 AM ETTSLA$349.37+6.05(+1.76%)Tesla and SpaceX Have Lost $457 Billion in Two Days7:21:49 AM ETLLY$1,353.00-14.10(-1.03%)BRIEF-Eli Lilly & Hims & Hers Health Announce Agreement To Expand Access To Zepbound & Foundayo7:20:47 AM ETMRNA$252.92+11.72(+4.86%)BRIEF-Moderna Expects Total Revenue Growth Of 15% To 25% In 20267:18:41 AM ETEGP$193.86-7.14(-3.55%)These Warehouse REITs Are Riding the E-Commerce Boom. Which Pays the Safest Dividend?7:17:09 AM ETWEST$9.54-0.82(-7.92%)What Westrock Coffee (WEST) Said on Its Q3 Earnings Call7:16:59 AM ETTSX:ENB$67.33-0.69(-1.01%)Canada's Enbridge Q3 EBITDA rises on higher gas transmission, distribution rates7:16:38 AM ETTSX:ENB$67.33-0.69(-1.01%)UPDATE 1-Enbridge's quarterly profit rises on strength in natural gas businesses7:16:06 AM ETPLTR$158.73+3.82(+2.47%)Palantir Shed Nearly 20% Over 12 Months: This Wall Street Desk Predicts 76% Gains Moving Forward7:15:57 AM ETBAM$53.90+1.44(+2.74%)Brookfield Asset Management Q3 fee-related earnings rise on Oaktree acquisition7:15:42 AM ETAAPL$340.00-4.40(-1.28%)Apple Is Virtually Insulated From Blue-Wave Pain Points7:15:30 AM ETAAPL$340.00-4.40(-1.28%)Apple Vs. Alphabet: The Midterms Just Separated Them from The Mag 7 Pack7:15:26 AM ETGOOG$280.73-1.14(-0.40%)Alphabet is The Best Positioned Hyperscaler for This Blue Wave AI-Energy Regulation Shift7:15:12 AM ET

CANF · AMEX

Can-Fite BioPharma Ltd.

$1.68 +0.08 (+5.00%)

Company overview

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate, Piclidenoson, has completed a Phase III clinical trial for the treatment of psoriasis and a Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson, which is in a Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as a Phase IIb trial for the treatment of non-alcoholic steatohepatitis, and CF602, which is in a preclinical trial for the treatment of erectile dysfunction. In addition, the company develops a commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd.

Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Market cap
$2.2M
Employees
5
Headquarters
Petah Tikva
Website
canfite.com
CEO
Pnina Fishman
Listed
November 6, 2012
P/E
-1.87
Dividend yield
0.00%

Company financials

Revenue
$560,000
Gross profit
$560,000
Operating income
-$8.9M
EBITDA
-$8.9M
Net income
-$8.8M
EPS
-$0.90
Total assets
$9.5M
Total debt
$71,000
Gross margin
100.00%
Net margin
-1,571.25%
Earnings yield
-53.57%

Price chart

1.322.533.744.956.16
CANF 1D AMEX O1.69H1.69L1.57C1.60-0.07 (-4.13%)Vol9.99K

News

LiveHeadlines show up as soon as they are ingested, with ticker, type, source, and time.

Pro

15-min delayYour Free plan is delayed 15 minutes. Pro opens the live desk.

Start 7-day free trial See live plans

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans

Since 2020This range is older than the last year on your plan. Pro opens articles since 2020.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CANFCan-Fite BioPharma Ltd. Press release Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study GlobeNewswire
CANFCan-Fite BioPharma Ltd. Stock news Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Benzinga
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Wall Street is Watching These Biotechs GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market GlobeNewswire
CANFCan-Fite BioPharma Ltd. Press release Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy GlobeNewswire
See more
FAQ

Questions about Can-Fite BioPharma Ltd.

What does Can-Fite BioPharma Ltd. do?
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate, Piclidenoson, has completed a Phase III clinical trial for the treatment of psoriasis and a Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson, which is in a Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as a Phase IIb trial for the treatment of non-alcoholic steatohepatitis, and CF602, which is in a preclinical trial for the treatment of erectile dysfunction. In addition, the company develops a commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd.
What is CANF's market cap?
Can-Fite BioPharma Ltd. (CANF) is a listed stock with a live quote. The latest market cap on this page is $2.2M.
Where is Can-Fite BioPharma Ltd. headquartered?
Can-Fite BioPharma Ltd. is headquartered in Petah Tikva.
How do I get CANF news from the API?
Call GET /v1/news?tickers=CANF. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CANF news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CANF, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CANF price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs